CAR-T therapy could “alter the treatment paradigm” of multiple sclerosis
Drug Discovery World
JANUARY 5, 2024
Kyverna Therapeutics has revealed plans to progress to Phase II trials of KYV-101 for multiple sclerosis (MS) following a green light from the US Food and Drug Administration (FDA). CAR T-cell therapy involves modifying a patient’s T cells to recognise and remove B cells in the patient’s body.
Let's personalize your content